30 results about "Oncology" patented technology

Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.

The present invention provides methods, compositions and kits for the prognosis, characterization and treatment of cancers. The methods, compositions and kits of the invention comprise a set of markers whose expression is correlated with estrogen receptor beta function. Therefore, the methods, compositions and kits of the invention find particular use in endocrine-related cancers such as breast cancers.

The invention discloses a gastric cancer risk prediction method and system, computer equipment and a readable storage medium, and relates to the technical field of cancer risk detection. The method comprises the following steps: collecting original data; preprocessing the original data; establishing a risk assessment model and training the risk assessment model; and utilizing the trained risk assessment model to predict a result based on the to-be-tested set. According to the technical scheme provided by the invention, the risk of suffering from gastric cancer can be accurately predicted for reference of doctors.

The invention belongs to the technical field of pharmaceuticals and particularly relates to a cervical-cancer-resistant composition and an application thereof. The cervical-cancer-resistant composition disclosed by the invention is characterized by comprising 160-200 parts of ginseng, 15-30 parts of cassia twig, 30-80 parts of curcuma zedoary and 60-120 parts of selfheal. The cervical-cancer-resistant composition has the beneficial effects that experiments prove that the composition has an efficient inhibiting effect for cervical cancer; 2, cancer cells are inhibited, and meanwhile, the immune system is remarkably improved; and 3, the anti-cancer mechanism of the composition is possible as follows: the transportation function of an L-amino acid transporter 1 is inhibited by effective ingredients in the drugs, so that a favorable anti-cancer effect is achieved.

The invention provides a composition for treating lung cancer. The composition comprises erlotinib hydrochloride tablets and crocin albumin nanoparticles. By adopting the composition, the defects thatin the prior art combined medicines for effectively treating lung cancer are not available are overcome, and the composition which is remarkable in synergetic effect in treating lung cancer is provided.

Polynucleotides useful for detecting copy number variation of RNU2 sequences and methods of assessing risk of developing breast or ovarian cancer using molecular combing and/or detection or quantification of BRCA1 expression.

A pharmaceutical composition for treating cancer, containing a crRNA and an endonuclease as active ingredients is disclosed. The composition can be customized according to the needs of patients or cell types by specifically treating cancer cells on the basis of specific binding properties of DNA and RNA. The nuclease activity of a CRISPR PLUS system, containing both an endonuclease and an exonuclease can be activated by means of the binding between crRNA and a gene specifically found in cancer cells. Therefore, the cancer treatment effect of the composition is more specific than that of other anti-cancer agents that have been developed up till now.

Compositions and methods to treat prostate cancer with the compound camalexin and its structural analogs. Camalexin increases ROS production and decreases the proliferation of prostate cancer cells, especially aggressive prostate cancer cells.

Disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising measuring the level of one or more polyamines in a fluid sample obtained from the subject, measuring at a variable selected from the group consisting of age, prostate volume (PV), prostate-specific antigen (PSA), digital rectal examination (DRE), and combinations thereof. Also disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising obtaining a score value based on previously disclosed variables to predict the likelihood of the subject developing or having prostate cancer.

The present invention relates to methods of predicting the probability of pathological complete response (pCR) of a breast cancer patient upon neo-adjuvant chemotherapy, to methods for selecting a breast cancer treatment, to methods of treatment of breast cancer, and to methods of prognosis of breast cancer upon breast cancer treatment.

The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).

The invention discloses an application of GSK1838705a in ALK + ALCL and crizotinib-resistant ALK + ALCL. GSK1838705a is used for treating tumors, GSK1838705a is used for treating ALK + ALCL, and GSK1838705a is used for treating ALK + ALCL of crizotinib-resistant patients. GSK1838705a can inhibit the proliferation of ALK + ALCL cell line and crizotinib-resistant ALK + ALCL cell line, and induces the apoptosis of the cell line. Compared with the blank control group, GSK1838705a significantly inhibits the expression of p-IGF, p-ALK, p-AKT, p-STATT3 in the ALK + ALCL cell line and the crizotinib-resistant ALK + ALCL cell line, and the expression of activated apoptosis-related proteins is increased significantly. GSK1838705a significantly inhibits the growth of transplanted tumors in mice, andimproves the survival time of transplanted tumor mice, so that GSK1838705a shows anti-tumor effects in the in vivo and in vitro experiments, and a new use for ALK + ALCL and crizotinib-resistant ALK +ALCL is provided.

Provided are a kit and method of in vitro auxiliary diagnosis of pancreatic cancer. Particularly, provided is an application of human serum miR-25 as a test target in preparing a pancreatic cancer diagnostic reagent. Also provided is a kit for in vitro auxiliary diagnosis of pancreatic cancer, the kit comprising primers and probes for real-time fluorescent quantitative PCR detection of human serum miR-25.

The invention provides an application of combination of NK cells and TFPI in prevention and treatment of nasopharyngeal carcinoma. It is found for the first time that a tissue factor pathway inhibitor (TFPI) serving as a natural killer cell (NK cell) anti-nasopharyngeal carcinoma synergist can promote the NK cell to inhibit growth of nasopharyngeal carcinoma cell transplantation tumor and remarkably improve the curative effect of the NK cell in the aspect of nasopharyngeal carcinoma prevention and treatment, so that the TFPI and the NK cell are combined for use, the synergistic interaction effect of the TFPI and the NK cell is exerted, the new application of the NK cells and the TFPI is provided, a new therapeutic medication scheme is provided for treatment of the nasopharyngeal carcinoma, and the NK cells and the TFPI have extremely high market value in the aspect of prevention and treatment of the nasopharyngeal carcinoma.

The invention provides a drug for treating cancer and tibia disease and a preparation method of the drug, and particularly relates to the technical field of drugs and preparation thereof. The drug fortreating cancer and tibia disease is characterize by comprising the following components in part by mass: 10-20 parts of wild apostichopus japonicus, 20-60 parts of herba taraxaci, 5-10 parts of ganoderma lucidum, 5-15 parts of lycium ruthenicum, 5-15 parts of aged dark tea, 5-15 parts of Tieguanyin tea, 5-15 parts of selenium-enriched tea, 5-15 parts of Baigong tea 10, 10-15 parts of herba cistanche, 15-20 parts of pericarpium citri reticulatae, 10-15 parts of fructus mori, 5-10 parts of Kunlun chrysanthemum, 5-10 parts of herba saussurea involucratae and 5-15 parts of tea cream, and the I11type alcohol extraction matrix is 200 parts of aged vinegar. The drug for treating cancer and tibia disease has remarkable effect on cancer, liver cancer in early, middle and late stage and multiplemetastatic diseases, and reduces the side effects of radiotherapy and chemotherapy.

The invention discloses a traditional Chinese medicine composition for treating liver cancer and a preparation method thereof, and relates to the technical field of medicines for treating liver cancer, and the traditional Chinese medicine composition for treating liver cancer comprises the following raw material components in parts by weight: 1.5-2.5 parts of centipedes, 4.5-5.5 parts of earthworms, 4.5-5.5 parts of ground beetles, 4.5-5.5 parts of dung beetles and 4.5-5.5 parts of damp worms. The traditional Chinese medicine composition for treating liver cancer provided by the invention can strengthen the body resistance, resist cancer, soften hard mass, remove food retention, promote blood circulation to remove blood stasis, detoxify, dissipate stagnation, promote menstruation to promote diuresis, and remove toxic rot of liver and kidney meridians; the traditional Chinese medicine composition adopts natural traditional Chinese medicines as raw material components, combats poison with poison, does not need chemotherapy, radiotherapy and operation, has no side effect, is low in price, can effectively treat liver cancer, has an effective rate of more than 90%, has a higher treatment survival rate, and does not need to take medicine for a long time after curing. Artemisia capillaris, poria cocos and endothelium corneum gigeriae galli are added, so that symptoms of jaundice, liver ascites and dyspepsia of liver cancer patients can be respectively and specifically treated. The three conditions can be decocted with water to be taken. The powder can be directly ground into capsules without the three conditions.

The invention relates to establishment and improvement of a preoperative evaluation and prediction model for satisfactory tumor cell deduction of advanced ovarian cancer. Herein, improved modeling is carried out on the basis of the Sduidan score table; and serological HE4 and ROMA indexes are added, the HE4 calculated according to the data is larger than 264.7 pmol/L, the CA125 calculated according to the data is larger than 545.6 U/ml, the ROMA indexes calculated according to the data are larger than 90.0%, and the prediction scores are given to be one score respectively; and then two different radiology department high-age doctors perform secondary radiology reading scoring to calculate predicted scores of all cases; and finally, an ROC curve is drawn according to a prediction score and an operation result to obtain an area AUC under a subject working curve, and evaluation of the model is carried out to predict the clinical value of the unsatisfactory tumor cell deduction operation of the advanced ovarian cancer patient. The prediction value of the prediction model is higher than that of a Suidan prediction model. When the model is used for predicting the dissatisfactory tumor cell deficit operation, the sensitivity is obviously higher than that of a Suidan score table, which provides a basis with a certain prediction value for clinicians to judge whether the dissatisfactory tumor cell deficit operation can be performed or not.

The invention provides a gold nanostar for identifying and degrading PD-L1 on the surfaces of prostate cancer cells as well as a preparation method and application of the gold nanostar, and relates to the technical field of biological medicines. According to the invention, PD-L1 binding peptide, autophagy induction peptide and the gold nanostar are utilized for the first time, and a nano-particle capable of identifying and efficiently degrading PD-L1 on the surfaces of prostate cancer cells are successfully constructed. According to the method, the PD-L1 binding peptide and the autophagy induction peptide are grafted to the surface of the gold nanostar, and PD-L1 is recognized and degraded through a nanodevice, so immune escape of prostate cells is inhibited, anti-tumor immunity is enhanced, the progress of prostate cancer is inhibited, and the purpose of treating prostate cancer is achieved.

Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.

Compositions and methods for transient immunodepletion of specific subsets of a subject's immune cells are disclosed. The methods generally include administering to the subject an effective amount of a radiolabeled antibody against CD19, CD20, CD33, CD38, CD45RA, CD52, or a combination thereof. The effective amount of the radiolabeled antibody depletes at least 50% of the targeted immune cells, and less than 20% of the subject's stem cells. When used alone, these methods may target lymphomas, leukemias, and myelomas, and/or may additionally allow repopulation of non-autoreactive immune cells in patients with an autoimmune disease. When these methods precede certain cell-based therapies, such as adoptive cell therapy and/or hematopoietic stem cell therapy, the methods are able to enhance the outcome of the cell-based therapies while minimizing adverse effects.